* Aziyo Biologics Inc AZYO.OQ AZYO.O is expected to show
a
rise in quarterly revenue when it reports results on May 10.
* The Silver Spring Maryland-based company is expected to
report
a 19.2% increase in revenue to $13.7 million from $11.5 million
a year ago, according to the estimate from one analyst, based on
Refinitiv data.
* Refinitiv's mean analyst estimate for Aziyo Biologics Inc
is
for a loss of 54 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts had fallen by
about 10.1%
in the last three months.
* Wall Street's median 12-month price target for Aziyo
Biologics
Inc is $12, above its last closing price of $2.28.
This summary was machine generated May 9 at 00:20 GMT. All
figures in US dollars unless otherwise stated